Zelapar
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Zelapar (selegiline; Valeant) is a novel rapidly disintegrating tablet formulation of the monoamine oxidase B (MAO-B) inhibitor selegiline. Adding Zelapar as an adjuvant to levodopa reduces the motor complications after a few hours of response to levodopa ingestion. The MAO-B enzyme primarily catalyzes the conversion of dopamine and phenylethylamine in the brain. Selegiline binds to the MAO-B enzyme site and renders it inactive to provide a longer duration of dopamine in the synapse, thereby prolonging the therapeutic effect from levodopa therapy.
Analyst Outlook
Zelapar (selegiline; Valeant) has been overshadowed by the subsequent launch of Teva’s monoamine oxidase B (MAO-B) inhibitor Azilect (rasagiline), largely due to Azilect’s favorable tolerability and lack of harmful metabolites that are associated with selegiline. Zelapar was launched in the US in 2006 and has thus far generated disappointing sales. Although the novel buccal formulation showed promise for dysphagic patients, Zelapar has rapidly disappeared from the market.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Zelapar : Parkinson’s disease
LIST OF FIGURES
6 Figure 1: Zelapar (selegiline; Valeant) SWOT analysis in Parkinson’s disease
8 Figure 2: Datamonitor Healthcare’s drug assessment summary for Zelapar in Parkinson’s
disease
8 Figure 3: Datamonitor Healthcare’s drug assessment summary for Zelapar in Parkinson’s
disease
LIST OF TABLES
4 Table 1: Zelapar (selegiline; Valeant) – drug profile
5 Table 2: Pivotal Phase III clinical trial data for Zelapar (selegiline; Valeant) in Parkinson’s
disease
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Retinal Disorders (AMD and DME) Pulse 
Sign up to the